PA007456: In vivo Grade Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B9E9)
The in vivo grade recombinant anti-human CD20 Mouse IgG2a Kappa monoclonal antibody was produced in mammalian cells.
Clone: B9E9.
Isotype: Mouse IgG2a Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: B9E9) specifically binds to human CD20.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD20 protein.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Shipping: The in vivo grade recombinant anti-human CD20 antibodies (clone of B9E9) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human CD20 antibody (B9E9):
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
Morita, D., et al. (2024). J Immunother Cancer. 2024 Dec 9;12(12):e009741. doi: 10.1136/jitc-2024-009741. PMID: 39653552
Fluorochrome-conjugated monoclonal antibodies, including anti-human CD20 (clone B9E9), were used to stain human cells for flow cytometry analysis with Gallios or BD FACSymphony cytometers at Texas Children’s Hospital. Eight weeks post-injection, PBMCs from humanized mice were stained with anti-human CD45 to confirm humanization. Other antibodies, such as anti-CD3 (UCHT1), CD4 (SK3), and CD8 (RPA-T8), were used to assess immune cell profiles, demonstrating T-cell redirection for enhanced antitumor immunity.
Tags: anti-human CD20 B9E9; anti-human CD20 B9E9 antibody
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Forero, A., et al. (2004). Blood. 2004 Jul 1;104(1):227-36. doi: 10.1182/blood-2003-09-3284. PMID: 14996706
A phase 1 trial assessed the safety, pharmacokinetics, and immunogenicity of a tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) in patients with B-cell non-Hodgkin lymphoma (NHL) for pretargeted radioimmunotherapy (PRIT). The B9E9FP (anti-human CD20) targeted HLA class I/peptide complexes, showing in vivo activity when combined with anti-viral T cells, supporting further clinical development with autologous CTLs from vaccination or ex vivo expansion.
Tags: anti-human CD20 B9E9 antibody in vivo; anti-human CD20 B9E9 in animal model
An oncolytic measles virus engineered to enter cells through the CD20 antigen
Bucheit, A. D., et al. (2003). Mol Ther. 2003 Jan;7(1):62-72. doi: 10.1016/s1525-0016(02)00033-3. PMID: 12573619
An oncolytic measles virus (MV) was engineered to enter CD20(+) target cells via a single-chain (scFv) anti-CD20 antibody (B9E9) interaction with the CD20 antigen in non-Hodgkin’s lymphoma (NHL) models. The virus demonstrated enhanced oncolytic activity in vivo against CD20(+) tumors, showing equivalent effects on CD20(-) tumors, highlighting the clinical relevance of B9E9 (anti-human CD20) for targeted viral therapy.
Tags: anti-human CD20 B9E9 antibody in animal model; anti-human CD20 B9E9 in cancer research
Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice
Savage, P., et al. (2002). Int J Cancer. 2002 Apr 1;98(4):538-44. doi: 10.1002/ijc.10219. PMID: 11920616
The B9E9 scFvSA fusion protein (anti-human CD20) targeted HLA-A2/M1 complexes to Daudi cells, enabling CTL-mediated killing in vitro at dilutions as low as 100 pg/ml. In vivo SCID mouse assays showed that only one of four mice receiving B9E9 scFvSA, HLA-A2/M1 complexes, and anti-HLA-A2/M1 CTLs developed a tumor, supporting clinical development with autologous CTLs.
Tags: anti-human CD20 B9E9 in human tumor model; function of anti-human CD20 B9E9
Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes
Savage, P., et al. (2002). Br J Cancer. 2002 Apr 22;86(8):1336-42. doi: 10.1038/sj.bjc.6600223. PMID: 11953895
The B9E9 scFvSA fusion protein (anti-human CD20 mAb) delivered HLA-A2/class I peptide complexes to HLA class I-negative Daudi cells. Flow cytometry confirmed retention of targeted HLA-A2/M1 complexes, and in vitro CTL responses were observed in PBMCs pre-treated with B9E9 scFvSA. The B9E9 fusion protein, currently in clinical trials for B-cell lymphoma with radiolabeled biotin, demonstrated effective targeting for CTL induction.
Tags: bioactivity of anti-human CD20 B9E9; anti-human CD20 B9E9 antibody of low endotoxin
For more references about anti-human CD20 antibody (B9E9), please contact our scientific support team with message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody
Syd Labs provides the following recombinant anti-human CD20 monoclonal antibodies:
In vivo grade recombinant anti-human CD20 antibodies (clone 2H7)
In vivo grade recombinant anti-human CD20 antibodies (clone B9E9)